Guangzhou Wondfo Biotech Co.,Ltd

SZSE:300482 Stock Report

Market Cap: CN¥8.0b

Guangzhou Wondfo BiotechLtd Future Growth

Future criteria checks 4/6

Guangzhou Wondfo BiotechLtd is forecast to grow earnings and revenue by 61.2% and 19.3% per annum respectively. EPS is expected to grow by 61.1% per annum. Return on equity is forecast to be 8.2% in 3 years.

Key information

61.2%

Earnings growth rate

61.07%

EPS growth rate

Medical Equipment earnings growth22.5%
Revenue growth rate19.3%
Future return on equity8.22%
Analyst coverage

Low

Last updated28 Apr 2026

Recent future growth updates

Recent updates

Analysis Article • Feb 17

Guangzhou Wondfo Biotech Co.,Ltd (SZSE:300482) Doing What It Can To Lift Shares

With a price-to-earnings (or "P/E") ratio of 22.7x Guangzhou Wondfo Biotech Co.,Ltd ( SZSE:300482 ) may be sending...
Analysis Article • Jan 17

These 4 Measures Indicate That Guangzhou Wondfo BiotechLtd (SZSE:300482) Is Using Debt Safely

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
Analysis Article • Nov 18

Returns On Capital At Guangzhou Wondfo BiotechLtd (SZSE:300482) Paint A Concerning Picture

What are the early trends we should look for to identify a stock that could multiply in value over the long term? One...
Analysis Article • Nov 01

Guangzhou Wondfo BiotechLtd's (SZSE:300482) Shareholders May Want To Dig Deeper Than Statutory Profit

Guangzhou Wondfo Biotech Co.,Ltd's ( SZSE:300482 ) healthy profit numbers didn't contain any surprises for investors...
Analysis Article • Sep 06

Cautious Investors Not Rewarding Guangzhou Wondfo Biotech Co.,Ltd's (SZSE:300482) Performance Completely

Guangzhou Wondfo Biotech Co.,Ltd's ( SZSE:300482 ) price-to-earnings (or "P/E") ratio of 19.5x might make it look like...
Analysis Article • Jul 27

Returns On Capital At Guangzhou Wondfo BiotechLtd (SZSE:300482) Paint A Concerning Picture

If we want to find a potential multi-bagger, often there are underlying trends that can provide clues. One common...
Analysis Article • Apr 29

Guangzhou Wondfo BiotechLtd's (SZSE:300482) Solid Earnings May Rest On Weak Foundations

Guangzhou Wondfo Biotech Co.,Ltd ( SZSE:300482 ) just released a solid earnings report, and the stock displayed some...
Analysis Article • Mar 27

A Piece Of The Puzzle Missing From Guangzhou Wondfo Biotech Co.,Ltd's (SZSE:300482) Share Price

With a median price-to-earnings (or "P/E") ratio of close to 31x in China, you could be forgiven for feeling...
Analysis Article • Feb 29

There Are Reasons To Feel Uneasy About Guangzhou Wondfo BiotechLtd's (SZSE:300482) Returns On Capital

If we want to find a potential multi-bagger, often there are underlying trends that can provide clues. Ideally, a...

Earnings and Revenue Growth Forecasts

SZSE:300482 - Analysts future estimates and past financials data (CNY Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20283,362585N/A6984
12/31/20272,934492N/A6365
12/31/20262,580422N/A5855
3/31/20261,868-168553830N/A
12/31/20252,087-63158463N/A
9/30/20252,5742599241N/A
6/30/20252,735395-141105N/A
3/31/20253,004532-194100N/A
12/31/20243,06556243362N/A
9/30/20242,942524107538N/A
6/30/20242,852509230624N/A
3/31/20242,794502289664N/A
12/31/20232,765488-104329N/A
9/30/20232,989357116569N/A
6/30/20233,136354-56459N/A
3/31/20233,8874971,2681,818N/A
1/1/20235,6811,1971,0991,682N/A
9/30/20225,5501,2479051,472N/A
6/30/20225,5381,2578981,461N/A
3/31/20225,2901,383-270287N/A
12/31/20213,361634208665N/A
9/30/20213,14569518621N/A
6/30/20213,060741-1557N/A
3/31/20212,956692113594N/A
12/31/20202,8116346421,062N/A
9/30/20202,821663657886N/A
6/30/20202,7116308851,053N/A
3/31/20202,172413595775N/A
12/31/20192,072387N/A310N/A
9/30/20191,921375N/A329N/A
6/30/20191,817352N/A296N/A
3/31/20191,748325N/A232N/A
12/31/20181,650308N/A248N/A
9/30/20181,542280N/A198N/A
6/30/20181,498264N/A175N/A
3/31/20181,323231N/A186N/A
12/31/20171,145211N/A169N/A
9/30/2017921181N/A51N/A
6/30/2017747174N/A100N/A
3/31/2017624154N/A116N/A
12/31/2016547145N/A112N/A
9/30/2016525158N/A143N/A
6/30/2016486147N/A141N/A
3/31/2016450131N/A145N/A
12/31/2015429125N/A132N/A
9/30/2015382106N/A108N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: 300482 is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.4%).

Earnings vs Market: 300482 is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: 300482 is expected to become profitable in the next 3 years.

Revenue vs Market: 300482's revenue (19.3% per year) is forecast to grow faster than the CN market (17.1% per year).

High Growth Revenue: 300482's revenue (19.3% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: 300482's Return on Equity is forecast to be low in 3 years time (8.2%).

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/07/02 08:36
End of Day Share Price 2026/07/02 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Guangzhou Wondfo Biotech Co.,Ltd is covered by 7 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Pei ChengChina Galaxy Securities Co., Ltd.
Binbin ZhangCitic Securities Co., Ltd.
Wen DaiHuatai Research